China Digest: Muliang eyes $40m Nasdaq IPO; neoX Biotech, Resproly raise fresh capital

China Digest: Muliang eyes $40m Nasdaq IPO; neoX Biotech, Resproly raise fresh capital

Source: Markus Winkler/Unsplash

02 February, 2021

5Y Capital inhalation therapy Muliang neoX Biotech Resproly

Printed by Unregistered user on Fri, 25 Jul 2025 13:10:38 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Venture Capital

China Deal Review: 2020 ends on high note as Dec records 191 PE-VC deals worth $9.1b

Trustbridge leads $500m round for Tencent-backed Chinese healthtech firm DXY

Read more from Greater China

Chinese e-commerce giants defend ‘instant retail’ strategy despite state pressure

Hong Kong-based crypto platform OSL Group raises $300m equity funding